TREATMENT OF GLIOMA BY ENGINEERED INTERLEUKIN-4-SECRETING CELLS

Citation
Js. Yu et al., TREATMENT OF GLIOMA BY ENGINEERED INTERLEUKIN-4-SECRETING CELLS, Cancer research, 53(13), 1993, pp. 3125-3128
Citations number
29
Categorie Soggetti
Oncology
Journal title
ISSN journal
00085472
Volume
53
Issue
13
Year of publication
1993
Pages
3125 - 3128
Database
ISI
SICI code
0008-5472(1993)53:13<3125:TOGBEI>2.0.ZU;2-H
Abstract
The ability of interleukin-4 (IL-4) to mediate an antitumor response t o human gliomas was studied in vivo in nude mice. To allow the effect of IL-4 to be exerted over a relatively short distance and at an optim al concentration, a transfected tumor cell line expressing a high leve l of IL-4 was used in mixed tumor transplantation assays. There was a significant inhibition of growth of the U87 human glioma line when the IL-4-secreting cell line, LT-1, was implanted s.c. with the glioma in 5 nude mice when compared to contralateral control tumors consisting of the U87 glioma and IL-4-negative control cells. In addition, there was a prolongation of survival when U87 along with IL-4-secreting cell s were implanted intracerebrally in 12 nude mice compared to 12 contro l nude mice implanted with U87 and IL-4-negative control cells and 11 control animals receiving U87 alone. Histological analysis 4 days afte r i.c. inoculation revealed the presence of a dramatic eosinophil infi ltrate and tumor necrosis. The absence of viable glioma cells as well as resolution of inflammation 19 days after treatment suggests the pot ential for complete tumor regression without ongoing inflammatory sequ elae resulting from cytokine treatment.